Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pyxis Oncology, Inc.

1.35
+0.11008.87%
Post-market: 1.30-0.0500-3.70%18:13 EDT
Volume:620.87K
Turnover:822.91K
Market Cap:83.63M
PE:-0.86
High:1.36
Open:1.26
Low:1.26
Close:1.24
Loading ...

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments

TIPRANKS
·
31 May

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)

TIPRANKS
·
20 May

Promising Developments and Risk-Reward Profile Justify Buy Rating for Pyxis Oncology

TIPRANKS
·
20 May

Pyxis Oncology Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
19 May

Pyxis Oncology Q1 EPS $(0.35) Misses $(0.29) Estimate

Benzinga
·
15 May

Pyxis Oncology Reports Q1 2025 Results: Net Loss Widens to $21.2M, EPS at ($0.35) Amid Absence of Prior Year One-Time Revenue

Reuters
·
15 May

BRIEF-Pyxis Oncology Q1 Net Income USD -21.158 Million

Reuters
·
15 May

Pyxis Oncology Q1 Basic EPS USD -0.35

THOMSON REUTERS
·
15 May

Pyxis Oncology Inc - Expects Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
15 May

Press Release: Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
15 May

Pyxis Oncology Inc. to Participate in RBC Capital Markets Global Healthcare Conference

Reuters
·
14 May

Pyxis Oncology Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
09 May

William Blair Sticks to Their Hold Rating for Pyxis Oncology (PYXS)

TIPRANKS
·
28 Apr

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

GlobeNewswire
·
26 Apr

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

Zacks
·
16 Apr

Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate

MT Newswires Live
·
26 Mar

Pyxis Oncology Highlights Strategic Focus on Lead Candidate

TIPRANKS
·
24 Mar

Promising Prospects for Pyxis Oncology: Buy Rating Affirmed on Strong Clinical Profile and Strategic Focus

TIPRANKS
·
19 Mar

Promising Clinical Developments and Strategic Focus Drive Buy Rating for Pyxis Oncology

TIPRANKS
·
19 Mar

Pyxis Oncology Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar